PHARMACHON • JUNE 16-18 • CHICAGO, IL
The perfect date: April 25th…because it’s not too hot, not too cold. All you need is a light jacket…Oh! And it’s also #NationalDNADay! National DNA Day is a global movement…
SAN RAFAEL, Calif., Nov. 19, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated…
Achondroplasia is the Most Common Cause of Dwarfism First Medicine Approved to Treat Children with Achondroplasia in Europe SAN RAFAEL, Calif., Aug. 27, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today…
via Clinical Trials Arena by William Newton. Vosoritide’s uncertain long-term efficacy may limit European coverage of what could be the first drug approved for dwarfism. Need to know Vosoritide is…
Source – Fierce Pharma. While BioMarin bested expectations with its second-quarter performance, the biotech is zeroed in on its two next-gen medicines. And no wonder: Those drugs, Voxogo and Roctavian, could completely…
via Anesthesiology News. Elizabeth A.M. Frost, MD The ninth in a series of capsules of pertinent information and precautions concerning rare disorders for the anesthesiologist. Click here for full article….